Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Alyi, I think from what I remember, will use NOUV hemp for their batteries. Its all happening in NY from what I understand. Its posted under the news tag on top of board fro Alyi.
PURA and NOUV are in Canada also. Plus Texas with nouv and Kaly, and nouv is now in NY with another company under ACI. Were becoming huge. Kali is the extractor for all of them.
I said financials should be good, filings could hit by next week...
What is wrong with this.
Oops Sorry got ahead of myself. Kaly or PURA has their filings or annual on the 15th due after an exstention. I was a week off, my bad.
Any kind of news from the partnership between Kaly, PURA, NOUV all reflect on each others progress. Just saying. Sorry if my posts don't fit your liking. Eighter way, USCH is thriving... Were going big here... Hang tight.
Everyone is reviving their orders of EverX from PURA. Check out comments on pura board. That's Nouv's CBD extracted by KALY for PURA. Orders are in demand, back orders are being produced. Its all real. Check the comments on pura board. Hold tight, financials should be good and filings ready to hit as soon as next week.
Its all comming together, Texas, filings, Kaly based with nouv in Texas, PURA in Canada, and in NY. Medical use from Texas hemp, pots gonna be legal in NY, already is in Canada. Reasearch results turning up positive for COPD, working on pain and diabetes. Man its all comming together, USCH and ACI. This is just going to keep rising. Hold on peeps, Don't flip or sell, watch this bad boy take off. I'm sure we will all be very happy, very soon. With everything all comming together, its a no-brainer. Get in now, or you can watch it all happen from your rear view mirror. Go NOUV and KALY, Gltua...
Lol, Lmfao. Really?? Lol so out of touch, no clue... NOUV going to be huge, after all no nouv no cultivation, no product, period.
Anyone, post L2
Trending up, keep her going, 35% one day followed by 16%. Lets see anoth 20% gain today..
7s in site, get the ask out.
2s imo
Don't let MMs and flippers beat this down today, we need to hold our ground, it will all be worth it when news hits.
Whales hoooo
Check out nouv, following suit with Kaly, huge news about to hit.
Not happening, you would know this if you were invested.
7s next, this is what I'm talking about. Kaly up, nouv up, huge things happening. Lets do this boys and girls.
New resistance at 2. Hit it boys and girls lets have a huge day. Kaly up big time, 100% buy on Barnhart.. Lets do this.
Hit the ask peeps, broke resistance yesterday, we can break the new resists,nice today before the weekend and in time for the news comming today and next week. Hold tight, hit the ask and enjoy the flight.
BS again. Lol
5 day chart...lol
$Kali(OTCMKTS)$ Real-time quotes & in-depth analysis, share trading ideas. https://www.webull.com/quote/otcmkts-kaly
Kali Inc (OTCMKTS: KALY) Breakout Looms On Improving Fundamentals
Source: InvestorsHub NewsWire
Kali Inc (OTCMKTS: KALY) Breakout Looms On Improving Fundamentals
?
April 4, 2019 -- InvestorsHub NewsWire -- Jim Bloom -- Kali Inc (OTCMKTS: KALY) resurgence is gathering pace as a spike in trading volume continues to affirm renewed investor interest. The stock has once again started surging after coming under immense short selling pressure at the start of the year.
KALY SHARE PRICE ANALYSIS
The announcement that the company is developing cannabis treatment for type 2 Diabetes is the latest catalyst fuelling the upside action. The company has also set sights on the $600 million cannabis beverage market with a new 25 mg CBD extract formulation, as it continues to strengthen its product line.
In addition, the company has inked a strategic partnership with Nouveau Life Pharmaceuticals Inc (OTCMKTS: NOUV) and Puration Inc (OTCMKTS: PURA) as part of an effort of coming up with cannabis pharmaceutical solutions. The trio has signed an agreement with Generex Biotechnology Corporation (OTCMKTS: GNBT) as part of the drive.
Investors have continued to push the stock up, in response to recent developments that affirm Kali-Extracts push for value in the multi-billion sector. After plunging to the $0.01 mark, the stock has once again started trending higher after powering through a tight trading range.
?
If recent price action activity is anything to go by, then Kali-Extracts could as well be on its way to 52-week highs of $0.03 mark. A rally followed by a close above the critical technical level should open the door for the stock to continue powering high on turning bullish.
ABOUT KALI-EXTRACTS
Kali-Extracts is a cannabis-focused company engaged in the research and development of cannabis treatments. The company is currently working on cannabis treatments for various therapies as well as chronic pain. It also provides Pharmaceuticals with cannabis extracts and health wellness products.
WHY IS KALI-EXTRACTS SURGING
Shares of Kali-Extracts are surging after a long period of consolidation on the company announcing plans to pursue opportunities in two multimillion industries. The company has embarked on a research and development drive as it seeks to come up with cannabis-infused treatments for addressing COPD and Type 2 Diabetes.
The new treatments will supplement the company’s pilot cannabis treatment for Chronic Obstructive Pulmonary Disease. Success on the development of cannabis treatments for addressing Type 2 Diabetes should expand the company’s footprint into the $64 billion diabetes market.
Even as the company continues to work on cannabis treatments, it is also in the process of strengthening its pipeline of products. Through a patented extraction process, the company has produced a 10mg formulation of Puration leading EVERx CBD sports product as it moves to make its debut in the $600 million Cannabis Beverage Market.
In addition to cannabis products development, Kaly also continues to generate revenue from its patented cannabis extraction processes.
Plans by Texas to remove hemp as a controlled substance is another development that continues to shore, Kali, extracts sentiments in the market. Such a move should enhance the company’s push for opportunities in the state, especially with its cannabis extraction lab.
“Just the type of market condition management is looking for to support the implantation of the previously announced cannabis extraction lab to be dedicated to the 100-acre hemp farm to be operated by partner Nouveau (NOUV) in Texas,” Kaly in a statement.
TEXAS OPPORTUNITY
The company has already inked a strategic partnership with Nouveau as part of its push for opportunities in Texas. The two are to join forces on the development of proprietary hemp cultivar expected to enhance Kaley’s extract development.
Enhancing operations in Texas part of Kaley’s push for value in the cannabis sector. The company has been exploring ways of enhancing its sales channel in pursuit of additional revenue streams. Early in the year, the company secured a $100,000 wholesale order for its Hemp4mula CBD infused Gummies.
BOTTOM LINE
Kaly’s share price does not provide an accurate reflection of the company’s tremendous potential. The company has continued to show how focused it is about pursuing opportunities with a diversified product line.
Development of cannabis-infused treatments for addressing various unmet medical needs provides clear evidence of how focused the company is about securing its long-term prospects. The company is also expanding its retail chain as it looks to generate optimum returns from its product line as well as extraction lab.
Price gains in the market look set to be the order of the day, on investors taking note of the tremendous opportunity at stake as the company continues to refine its product line.
We will be updating our subscribers as soon as we know more. For the latest updates on KALY, sign up below!
Disclosure: We have no position in any of the stocks mentioned and have not been compensated for this article.
×
iHub MobileInvestors HubFREE - In Google Play
VIEW
?
?
?
Support: 888-992-3836|NewsWire|Home|Log in
Boards
Hot!
Tools
Crypto
Streamer
Level 2
Quote
Chart
Level 2
Trades
News
Financials
Historical
Message Board
Kali, Inc. (PN) (USOTC)Kalytera Therapeutics(TSXV)
Kali Inc (OTCMKTS: KALY) Breakout Looms On Improving Fundamentals
Date :04/04/2019 @ 6:59PMSource :InvestorsHub NewsWireStock :Kali, Inc. (PN) (KALY)Quote :? 0.0172 0.0024 (16.22%) @ 9:30PM
Kali Inc (OTCMKTS: KALY) Breakout Looms On Improving Fundamentals
Print
Kali Inc (OTCMKTS: KALY) Breakout Looms On Improving Fundamentals
?
April 4, 2019 -- InvestorsHub NewsWire -- Jim Bloom -- Kali Inc (OTCMKTS: KALY) resurgence is gathering pace as a spike in trading volume continues to affirm renewed investor interest. The stock has once again started surging after coming under immense short selling pressure at the start of the year.
KALY SHARE PRICE ANALYSIS
The announcement that the company is developing cannabis treatment for type 2 Diabetes is the latest catalyst fuelling the upside action. The company has also set sights on the $600 million cannabis beverage market with a new 25 mg CBD extract formulation, as it continues to strengthen its product line.
In addition, the company has inked a strategic partnership with Nouveau Life Pharmaceuticals Inc (OTCMKTS: NOUV) and Puration Inc (OTCMKTS: PURA) as part of an effort of coming up with cannabis pharmaceutical solutions. The trio has signed an agreement with Generex Biotechnology Corporation (OTCMKTS: GNBT) as part of the drive.
Investors have continued to push the stock up, in response to recent developments that affirm Kali-Extracts push for value in the multi-billion sector. After plunging to the $0.01 mark, the stock has once again started trending higher after powering through a tight trading range.
?
If recent price action activity is anything to go by, then Kali-Extracts could as well be on its way to 52-week highs of $0.03 mark. A rally followed by a close above the critical technical level should open the door for the stock to continue powering high on turning bullish.
ABOUT KALI-EXTRACTS
Kali-Extracts is a cannabis-focused company engaged in the research and development of cannabis treatments. The company is currently working on cannabis treatments for various therapies as well as chronic pain. It also provides Pharmaceuticals with cannabis extracts and health wellness products.
WHY IS KALI-EXTRACTS SURGING
Shares of Kali-Extracts are surging after a long period of consolidation on the company announcing plans to pursue opportunities in two multimillion industries. The company has embarked on a research and development drive as it seeks to come up with cannabis-infused treatments for addressing COPD and Type 2 Diabetes.
The new treatments will supplement the company’s pilot cannabis treatment for Chronic Obstructive Pulmonary Disease. Success on the development of cannabis treatments for addressing Type 2 Diabetes should expand the company’s footprint into the $64 billion diabetes market.
Even as the company continues to work on cannabis treatments, it is also in the process of strengthening its pipeline of products. Through a patented extraction process, the company has produced a 10mg formulation of Puration leading EVERx CBD sports product as it moves to make its debut in the $600 million Cannabis Beverage Market.
In addition to cannabis products development, Kaly also continues to generate revenue from its patented cannabis extraction processes.
Plans by Texas to remove hemp as a controlled substance is another development that continues to shore, Kali, extracts sentiments in the market. Such a move should enhance the company’s push for opportunities in the state, especially with its cannabis extraction lab.
“Just the type of market condition management is looking for to support the implantation of the previously announced cannabis extraction lab to be dedicated to the 100-acre hemp farm to be operated by partner Nouveau (NOUV) in Texas,” Kaly in a statement.
TEXAS OPPORTUNITY
The company has already inked a strategic partnership with Nouveau as part of its push for opportunities in Texas. The two are to join forces on the development of proprietary hemp cultivar expected to enhance Kaley’s extract development.
Enhancing operations in Texas part of Kaley’s push for value in the cannabis sector. The company has been exploring ways of enhancing its sales channel in pursuit of additional revenue streams. Early in the year, the company secured a $100,000 wholesale order for its Hemp4mula CBD infused Gummies.
BOTTOM LINE
Kaly’s share price does not provide an accurate reflection of the company’s tremendous potential. The company has continued to show how focused it is about pursuing opportunities with a diversified product line.
Development of cannabis-infused treatments for addressing various unmet medical needs provides clear evidence of how focused the company is about securing its long-term prospects. The company is also expanding its retail chain as it looks to generate optimum returns from its product line as well as extraction lab.
Price gains in the market look set to be the order of the day, on investors taking note of the tremendous opportunity at stake as the company continues to refine its product line.
We will be updating our subscribers as soon as we know more. For the latest updates on KALY, sign up below!
Disclosure: We have no position in any of the stocks mentioned and have not been compensated for this article.
Partners
Marijuana Stocks
Stock Price
?
BOOOOOOOOOOOOM, WERE GOING TO 2S, LET HER RIP PEEPS.
17 resistance, lets knock it down
Lets see another 35% gainer today.
I know, and they sell lower than the current pps. Kinda fishy imo.. As though there's an agenda
Catch my drift?
Lets close the gap here and we continue to fly north.
Looking at 2s today...
Here we go, squeeze them shorties.
Yesterday, the short sales reported by FINRA exceeded 60% of total volume on both ALYI and KALY.
Two Stocks Ready To Run Could Go Even Higher On Short Squeeze
Source: InvestorsHub NewsWire
Two Stocks Ready To Run Could Go Even Higher On Short Squeeze
New York, NY -- April 3, 2019 -- InvestorsHub NewsWire -- www.nextbigticker.com -- Alternet Systems, Inc. (USOTC: ALYI) and Kali-Extracts, Inc. (USOTC: KALY) both came out with strong business plan supporting news yesterday and both had a jump in average trading volume. Today, both are pushing past Moving Average prices and seeing MACD crosses in spite of large market maker offers that runaway when charged. Yesterday, the short sales reported by FINRA exceeded 60% of total volume on both ALYI and KALY.
?
ALYI yesterday announced a potential $20 million order for the company’s electric motorcycles that could result from a series of strategic meetings next week. The stock is reacting bullishly and now the short squeeze could add to PPS appreciation.
ALYI is trading way above its $0.014 200 DAY MA and on the verge of breaking through its $0.029 50 DAY MA. The MACD is on its way to a cross and the Candlestick Pattern is Bullish Harami.
ALYI has a 52-Week High of over $0.06 and an analyst recommended Target PPS of $0.09. Momentum today that sees a close above $0.029 can take this stock to the next level all the way back to its $0.06 52-Week High with a potential upside to the $0.09 Target PPS.
?
KALY revealed yesterday for the first time ongoing patented cannabis extract Type 2 Diabetes Treatment research the company had previously kept under wraps adding to the recently published research results from the company’s pilot Chronic Obstructive Pulmonary Disease (COPD) treatment evaluation. The press release yesterday indicated two more cannabis extract health issue treatments are also soon to be revealed. KALY trading has shot to the OTC top 25 most actively traded list with the PPS edging toward a breakout. The PPS is above the 200 Day MA and has now broken past the 50 Day MA following a MACD cross. The candlestick analysis is indicating VERY BULLISH and now the short squeeze could add to PPS appreciation.
KALY Potential PPS Run From $0.01 to $0.04 On Way To $0.10
KALY has the potential to run from its $0.01 PPS level to $0.10 in the near term. Shortly after the 2018 Q4 acquisition of the patented cannabis extraction process, the company PPS shot from sub-penny land to almost $0.04 on volume that put it in the top 20 most actively traded stocks on the OTC Market. The PPS retraced back to $0.01 and has been holding that price with a healthy trading volume. With KALY’s patented cannabis pharmaceutical research now coming to light, the PPS is positioned to shoot past the recent $0.04 highs to a level putting it on par with some of the other penny cannabis stock contenders. A $0.10 PPS is a reasonable milestone following the company filing its upcoming annual reported expected to include the company posting its first revenue derived from its cannabis extraction process. The company filed an extension on the 2018 annual report with the report itself now expected within the next 15 days.
KALY is providing CBD extracts for over $1 million worth of CBD infused water produced by Puration, Inc. (USOTC: PURA), and KALY has also introduced its own CBD infused gum. KALY is also implementing an extraction lab to process biomass from Nouveau’s (USOTC: NOUV) 100 acer hemp farm.
Following the acquisition of the patented cannabis extraction process late last year and the corresponding jump in price and trading volume, the OTC Markets flagged the company in response to the jump in activity. The company has responded by updating all its OTC Markets required reports. Management is likely to mitigate the OTC Market’s concerns sooner or later and see the flag removed which will likely be yet another impetus fueling a KALY PPS run.
Management engaged Goldman Small Cap Research to conduct analyst coverage of the company and file an initial analyst report: KALY Research Report
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.
Source: www.nextbigticker.com
Two Stocks Ready To Run Could Go Even Higher On Short Squeeze
Source: InvestorsHub NewsWire
Two Stocks Ready To Run Could Go Even Higher On Short Squeeze
New York, NY -- April 3, 2019 -- InvestorsHub NewsWire -- www.nextbigticker.com -- Alternet Systems, Inc. (USOTC: ALYI) and Kali-Extracts, Inc. (USOTC: KALY) both came out with strong business plan supporting news yesterday and both had a jump in average trading volume. Today, both are pushing past Moving Average prices and seeing MACD crosses in spite of large market maker offers that runaway when charged. Yesterday, the short sales reported by FINRA exceeded 60% of total volume on both ALYI and KALY.
?
ALYI yesterday announced a potential $20 million order for the company’s electric motorcycles that could result from a series of strategic meetings next week. The stock is reacting bullishly and now the short squeeze could add to PPS appreciation.
ALYI is trading way above its $0.014 200 DAY MA and on the verge of breaking through its $0.029 50 DAY MA. The MACD is on its way to a cross and the Candlestick Pattern is Bullish Harami.
ALYI has a 52-Week High of over $0.06 and an analyst recommended Target PPS of $0.09. Momentum today that sees a close above $0.029 can take this stock to the next level all the way back to its $0.06 52-Week High with a potential upside to the $0.09 Target PPS.
?
KALY revealed yesterday for the first time ongoing patented cannabis extract Type 2 Diabetes Treatment research the company had previously kept under wraps adding to the recently published research results from the company’s pilot Chronic Obstructive Pulmonary Disease (COPD) treatment evaluation. The press release yesterday indicated two more cannabis extract health issue treatments are also soon to be revealed. KALY trading has shot to the OTC top 25 most actively traded list with the PPS edging toward a breakout. The PPS is above the 200 Day MA and has now broken past the 50 Day MA following a MACD cross. The candlestick analysis is indicating VERY BULLISH and now the short squeeze could add to PPS appreciation.
KALY Potential PPS Run From $0.01 to $0.04 On Way To $0.10
KALY has the potential to run from its $0.01 PPS level to $0.10 in the near term. Shortly after the 2018 Q4 acquisition of the patented cannabis extraction process, the company PPS shot from sub-penny land to almost $0.04 on volume that put it in the top 20 most actively traded stocks on the OTC Market. The PPS retraced back to $0.01 and has been holding that price with a healthy trading volume. With KALY’s patented cannabis pharmaceutical research now coming to light, the PPS is positioned to shoot past the recent $0.04 highs to a level putting it on par with some of the other penny cannabis stock contenders. A $0.10 PPS is a reasonable milestone following the company filing its upcoming annual reported expected to include the company posting its first revenue derived from its cannabis extraction process. The company filed an extension on the 2018 annual report with the report itself now expected within the next 15 days.
KALY is providing CBD extracts for over $1 million worth of CBD infused water produced by Puration, Inc. (USOTC: PURA), and KALY has also introduced its own CBD infused gum. KALY is also implementing an extraction lab to process biomass from Nouveau’s (USOTC: NOUV) 100 acer hemp farm.
Following the acquisition of the patented cannabis extraction process late last year and the corresponding jump in price and trading volume, the OTC Markets flagged the company in response to the jump in activity. The company has responded by updating all its OTC Markets required reports. Management is likely to mitigate the OTC Market’s concerns sooner or later and see the flag removed which will likely be yet another impetus fueling a KALY PPS run.
Management engaged Goldman Small Cap Research to conduct analyst coverage of the company and file an initial analyst report: KALY Research Report
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.
Source: www.nextbigticker.com
Hoping for a great day. USCH = partners 30, 30, 30%... PURA, KALY, NOUV
United States Cannibis Health
Partners 30, 30, 30% each. PURA, KALY, NOUV = USCH pharmaceutical s
Kali-Extracts Announces Developing Cannabis Pain Management Treatment For $83 Billion Market Specifically Targeting Cancer
Source: InvestorsHub NewsWire
Kali-Extracts Announces Developing Cannabis Pain Management Treatment For $83 Billion Market Specifically Targeting Cancer
Dallas, TX -- April 4, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced its ongoing research and development of a cannabis pain management treatment derived from the company’s patented cannabis extraction process. While cannabis for pain management treatment from cancer is not new, KALY is developing a proprietary extract that improves upon the cannabis treatments currently approved by the FDA. The FDA approved a marijuana treatment for aiding in the management of cancer symptoms and the side effects of other cancer treatments in1985. That drug, marinol, is a synthetic form of the marijuana cannabinoid THC and is used to treat both chemotherapy-induced nausea and HIV-related weight loss. The market for generic marinol is approximately $300 million per year. KALY’s cannabis extract is not a synthetic. The overall pain management treatment market is anticipated to reach $83 billion by 2024.
Earlier this week, KALY announced its ongoing research and development of a cannabis treatment for Type 2 Diabetes. Kali-Extracts, through its patented cannabis extraction process, is developing a variety of treatments for various health issues. KALY recently published a research report on its pilot cannabis treatment for Chronic Obstructive Pulmonary Disease (COPD). KALY is currently in the progress of beginning to disclose its additional research and development of cannabis extracts for additional health issues. The company currently has ongoing cannabis extract research and development targeting four specific health issues, COPD, Type 2 Diabetes, Cancer Pain Management and one additional health issue KALY plans to announce next week leading up to an online presentation with more detail on each of the treatment developments later this month. The market for Type 2 Diabetes is expected to be a $64 billion market by 2026. The market for COPD treatment is anticipated to reach $14 billion by 2025. Beyond the four specific cannabis therapies currently in various stages of research and development, KALY has a number of additional target therapies in its research pipeline.
In addition to its pharmaceutical developments, KALY is generating revenue from is patented cannabis extraction process delivering proprietary extracts for infusion into non-pharmaceutical commercial products. KALY announced last week finalizing it’s all new 25 mg CBD Extract formulation for beverage infusion. KALY’s patented extraction process already produces a 10 mg CBD formulation for Puration, Inc.’s (USOTC: PURA) (“PURA”) leading EVERx CBD Sports Water. KALY has also recently announced plans to provide commercial extraction for Nouveau, Inc. (USOTC: NOUV) (“NOUV”) in conjunction with NOUV’s recently announced 100-acre hemp farm.
KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. In addition developing pharmaceutical products internally and through partnerships, KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. The first revenue generating contracts signed in December of 2018 will be reflected in the company’s upcoming annual report.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Kali-Extracts Announces Developing Cannabis Pain Management Treatment For $83 Billion Market Specifically Targeting Cancer
Source: InvestorsHub NewsWire
Kali-Extracts Announces Developing Cannabis Pain Management Treatment For $83 Billion Market Specifically Targeting Cancer
Dallas, TX -- April 4, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced its ongoing research and development of a cannabis pain management treatment derived from the company’s patented cannabis extraction process. While cannabis for pain management treatment from cancer is not new, KALY is developing a proprietary extract that improves upon the cannabis treatments currently approved by the FDA. The FDA approved a marijuana treatment for aiding in the management of cancer symptoms and the side effects of other cancer treatments in1985. That drug, marinol, is a synthetic form of the marijuana cannabinoid THC and is used to treat both chemotherapy-induced nausea and HIV-related weight loss. The market for generic marinol is approximately $300 million per year. KALY’s cannabis extract is not a synthetic. The overall pain management treatment market is anticipated to reach $83 billion by 2024.
Earlier this week, KALY announced its ongoing research and development of a cannabis treatment for Type 2 Diabetes. Kali-Extracts, through its patented cannabis extraction process, is developing a variety of treatments for various health issues. KALY recently published a research report on its pilot cannabis treatment for Chronic Obstructive Pulmonary Disease (COPD). KALY is currently in the progress of beginning to disclose its additional research and development of cannabis extracts for additional health issues. The company currently has ongoing cannabis extract research and development targeting four specific health issues, COPD, Type 2 Diabetes, Cancer Pain Management and one additional health issue KALY plans to announce next week leading up to an online presentation with more detail on each of the treatment developments later this month. The market for Type 2 Diabetes is expected to be a $64 billion market by 2026. The market for COPD treatment is anticipated to reach $14 billion by 2025. Beyond the four specific cannabis therapies currently in various stages of research and development, KALY has a number of additional target therapies in its research pipeline.
In addition to its pharmaceutical developments, KALY is generating revenue from is patented cannabis extraction process delivering proprietary extracts for infusion into non-pharmaceutical commercial products. KALY announced last week finalizing it’s all new 25 mg CBD Extract formulation for beverage infusion. KALY’s patented extraction process already produces a 10 mg CBD formulation for Puration, Inc.’s (USOTC: PURA) (“PURA”) leading EVERx CBD Sports Water. KALY has also recently announced plans to provide commercial extraction for Nouveau, Inc. (USOTC: NOUV) (“NOUV”) in conjunction with NOUV’s recently announced 100-acre hemp farm.
KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. In addition developing pharmaceutical products internally and through partnerships, KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. The first revenue generating contracts signed in December of 2018 will be reflected in the company’s upcoming annual report.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Latest update on the dividend. Don't listen to peeps on here. Click on the news button top of screen if your looking for information.
USMJ and PURA Update Dividend Distribution Plans With PJET and NOUV To Include New Developments With WCVC and KALY
Source: InvestorsHub NewsWire
USMJ and PURA Update Dividend Distribution Plans With PJET and NOUV To Include New Developments With WCVC and KALY
Dallas, TX -- March 22, 2019 -- InvestorsHub NewsWire -- North American Cannabis Holdings, Inc. (USOTC: USMJ) (“USMJ”) and Puration Inc. (USOTC: PURA) (“PURA”) today published an update on the progress the two companies are making toward their respective planned dividend distributions. USMJ and PURA are sister companies sharing the same majority shareholder, ACI Conglomerated. In the 4th quarter of 2018, USMJ sold its AmeriCanna Cafe Restaurant business to an independently listed public holding company as part of a strategy to support the restaurant business with a dedicated public equity. The independently listed public holding company is Priority Aviation (USOTC: PJET). The transaction between USMJ and PJET includes a name change for PJET and a dividend of PJET shares to USMJ shareholders. Similarly, PURA sold its cannabis cultivation subsidiary to Nouveau (USOTC: NOUV). The PURA and NOUV transaction also includes a dividend of NOUV shares to PURA shareholders. The execution of the dividends is taking longer than anticipated, but the plans have not changed. The update below provides more details on the current status and progress of the two dividend distributions to include additional updates on the overall business.
USMJ and PJET Update and New WCVC developments
In the 4th quarter of 2018, USMJ spun off its AmeriCanna Cafe business through the execution of a securities exchange agreement between USMJ and PJET. USMJ has sold its AmeriCanna Cafe business in exchange for a convertible purchase note issued by PJET. Neither USMJ nor PJET are executing a reverse split in conjunction with this transaction. USMJ and PJET do plan to promptly convert the $1.5 million note into a number of common PJET shares sufficient to issue one PJET common share for every fifty shares of USMJ common shares issued and outstanding. All of the PJET common shares issued in conversion of the purchase note are slated for distributed to USMJ shareholders in a dividend distribution. Nothing has changed in regard to this plan since the execution of the agreement. The hurdle that remains in front of the dividend distribution is bringing PJET current with the OTC Markets reporting standards. The company has all the reports ready to file pending OTC Markets being ready to accept the filings. It appears that in an effort to improve OTC investor protections, that the OTC has upped its scrutiny of issuers applying to update their reporting, particularly with issuers that have recently undergone a significant business change or capital restructuring. Accordingly, we believe the OTC Markets review is taking longer than anticipated.
USMJ has made a number of announcements over the past several months regarding its business developments with its interests in PJET/AmeriCanna Cafe business and West Coast Venture Group (OTCBB: WCVC). WCVC is the owner and operator of the $3 million Colorado based Illegal Burger chain. WCVC has partnered with PJET/AmeriCanna Café in rolling out an AmeriCanna Cafe pilot featuring an AmeriCanna Cafe food truck in pop-up venues near a series of recreational marijuana dispensaries in Colorado. The partnership is going well and growing and shareholders can look for some exciting announcments coming soon about new developments in the relationship with WCVC.
PURA and NOUV and New Developments with KALY
In the 4th quarter of 2018, PURA sold its cannabis cultivation business to NOUV in exchange for a $1.2 million convertible note with a commitment that the note would promptly be converted into shares of NOUV and that those converted shares would be distributed in a stock dividend to the shareholders of PURA. The plan remains unchanged. Similar to the situation with USMJ and NOUV, the hurdle that remains in front of the dividend distribution is bringing NOUV current with the OTC Markets reporting standards. The company has all the reports ready to file pending OTC Markets being ready to accept the filings. It appears that in an effort to improve OTC investor protections, that the OTC has upped its scrutiny of issuers applying to update their reporting, particularly with issuers that have recently undergone a significant business change or capital restructuring. Accordingly, we believe the OTC Markets review is taking longer than anticipated.
Since NOUV and PURA executed the cannabis cultivation transaction, the cannabis cultivation business has been progressing with both its marijuana cultivation business in Canada and its US, revenue generating operations in the US. NOUV recently announced plans to plant 100 acers of Hemp this spring now that hemp farming is legal in the US under the 2018 Farm Act. NOUV and PURA have also partnered with Kali-Extracts (USOTC: KALY) (“KALY”) to work together in the development of cannabis pharmaceutical solutions. Together, the three companies have entered into an agreement with Generex Biotechnology (OTCQB: GNBT).
Management of USMJ, PURA, NOUV and PJET are overlapping as the controlling interest of all four companies is held by a private company, ACI Conglomerated. Management is confident that progress with bringing NOUV and PJET current with their OTC Markets reporting standards is progressing and within reach. Keep checking back for the latest updates.
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Steven Rash
CEO North American Cannabis Holdings, Inc.
info@aciconglomerated.com
+1-800-861-1350
Starting the trend upwards here.
This is around the time the MMs stopped their games yesterday. Its time to push her up. Lets do this boys and girls. Hit the ask here on in.
025, bmp...lol
Nothing really, not related to Kaly. Old BS.